Zipalertinib combo shows first-line promise in EGFR exon 20 NSCLC
TL;DR
Taiho and Cullinan reported that adding zipalertinib to platinum-based chemotherapy significantly extended progression-free survival versus chemotherapy alone in untreated NSCLC with EGFR exon 20 insertion, meeting the primary endpoint and prompting unblinding. The partners plan to pursue FDA first-line approval, complementing an FDA-accepted path for second-line use. If approved, zipalertinib would join a competitive landscape featuring J&J’s Rybrevant and AstraZeneca’s Zegfrovy in the EGFR exon 20 NSCLC niche.
Topics:businesshealthcare#egfr-exon-20-insertion#fda-approval#first-line-therapy#healthcare#nsclc#zipalertinib
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal Fierce Biotech
- New Taiho, Cullinan data heats up lung cancer drug battle BioPharma Dive
- Cullinan, Taiho score Phase III win for zipalertinib combo in first-line NSCLC FirstWord Pharma
- Taiho, Cullinan’s lung cancer drug passes Phase 3 test, lining up Rybrevant contest Endpoints News
- Zipalertinib plus chemo Phase III success in 1st-line NSCLC The Pharma Letter
Want the full story? Read the original reporting
Read on Fierce Biotech